Last reviewed · How we verify
GABA oral solution
At a glance
| Generic name | GABA oral solution |
|---|---|
| Also known as | gamma aminobutyric acid, lidocaine, distilled water, capsaicin, Gamma amino butyric acid |
| Sponsor | Aalborg University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer (PHASE3)
- Traditional vs. Minimally Invasive Decay Treatments in Primary Molars: An 18-month Split-mouth Randomized Study (NA)
- Multimodal Analgesia Effect on Post Surgical Patient (PHASE4)
- Effect of CBD on the Brain (PHASE2)
- A Trial Investigating the Pain-relieving Properties of Lu AG06474 in Healthy Adult Participants (PHASE1)
- A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms (PHASE3)
- A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms (PHASE3)
- Preoperative Gabapentin for Chronic Pain After Thoracotomy (GABATHOMIE). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GABA oral solution CI brief — competitive landscape report
- GABA oral solution updates RSS · CI watch RSS
- Aalborg University portfolio CI